Article Sidebar
Published:
Jun 6, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced nonsmall cell lung cancer
Abstract
Purpose: To investigate the clinical efficacy of anti-programmed cell death-1 (PD-1) immunotherapy in combination with chemotherapy in patients suffering from locally advanced non-small cell lung cancer (NSCLC).
Methods: A total of 110 NSCLC patients admitted in The Second Affiliated Hospital of Hainan Medical University, Haikou, China were randomly divided into two groups using envelope method. The control group was administered pemetrexed and cisplatin, and the study group was further treated with nivolumab. Each treatment cycle lasted for 21 days, and a total of 6 cycles were administered for the duration of therapy. The short-term objective response rate, adverse reactions, programmed cell death5 (PDCD-5), tumor necrosis factor-α (TNF-α), tumor necrosis factor-β1 (TGF-β1), and immune status indices were determined.
Results: The objective remission rate in study group was 79.25 % (42/53), which was higher than that in control group (61.40 %, 35/57; p < 0.05). After treatment, both groups showed higher levels of PDCD5 and TNF-α compared to their pre-treatment values, while demonstrating lower levels of TGF-β1. Furthermore, PDCD-5 and TNF-α in study group were higher than those in control group, while TGF-β1 was lower than that in control group (p < 0.05). In control group, the values of clusters of differentiation 3+(CD3+), 4+(CD4+), and 8+(CD8+) decreased after treatment, while the values of CD8+ increased after treatment. The CD3+, CD4+, and CD4+/CD8+ in study group were higher than those in control group, while CD8+ was lower than those in control group (p < 0.05).
Conclusion: Anti-PD-1 immunotherapy combination with chemotherapy in the treatment of local NSCLC stabilizes the immune system and improves the short-term efficacy of patients with advanced NSCLC. Further clinical trials are, however, required prior to application of this combination clinical practice.
